Want to see SE:INIT full AI Analyst Report?

Initiator Pharma A/S (INIT) Price & Analysis

0 Followers

INIT Stock Chart & Stats

kr2.29

kr0.25(10.92%)

At close: Jul 27 4:00 PM EDT

kr2.29

kr0.25(10.92%)

Day’s Range― - ―

52-Week Rangekr1.67 - kr3.65

Previous CloseN/A

Volume40.71K

Average Volume (3M)138.06K

Market Cap

kr136.56M

Enterprise Valuekr173.87M

Total Cash (Recent Filing)kr17.10M

Total Debt (Recent Filing)kr9.69M

Price to Earnings (P/E)―

Beta0.74

Next Earnings

Nov 20, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.40

Shares Outstanding68,452,890

10 Day Avg. Volume161,530

30 Day Avg. Volume138,063

Financial Highlights & Ratios

PEG Ratio0.00

Price to Book (P/B)4.31

Price to Sales (P/S)0.00

P/FCF Ratio-7.18

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)-0.63

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Focused Therapeutic StrategyA focused therapeutic strategy can concentrate limited clinical-stage resources on a defined medical need and specialist market. Maintaining a clear emphasis on male sexual and reproductive health may support coherent development priorities and a consistent long-term business identity.

Lead Drug CandidateHaving a clearly identified lead asset gives the company a concrete development pathway around which clinical work, regulatory planning, and future commercial preparation can be organized. Progress for pudafensinil therefore remains the central potential value driver over the coming quarters.

Targeted Patient OpportunityThe stated focus on erectile dysfunction patients who may not respond adequately to existing PDE5 inhibitors identifies a potentially differentiated treatment opportunity. If development supports this positioning, the candidate could address an unmet need within an established therapeutic category.

Bears Say

Pre-revenue Development ProfileNo revenue means the business has not yet demonstrated commercial product demand or an operating revenue base. Until a development asset reaches commercialization, financial performance will remain dependent on clinical progress and the company’s ability to secure additional funding.

Widening LossesThe substantial widening of net and operating losses indicates that expenditure is increasing faster than the company’s ability to generate income. Persistent losses can reduce financial resilience and require continued financing before the pipeline produces commercial returns.

Funding And Balance-sheet PressureHeavy cash burn alongside rising debt and sharply reduced equity weakens financial flexibility. This combination increases dependence on external funding and raises the risk that future financing may involve dilution or refinancing pressure while the company remains loss-making.

INIT FAQ

What was Initiator Pharma A/S’s price range in the past 12 months?

Initiator Pharma A/S lowest stock price was kr1.67 and its highest was kr3.65 in the past 12 months.

What is Initiator Pharma A/S’s market cap?

Initiator Pharma A/S’s market cap is kr136.56M.

When is Initiator Pharma A/S’s upcoming earnings report date?

Initiator Pharma A/S’s upcoming earnings report date is Nov 20, 2026 which is in 37 days.

How were Initiator Pharma A/S’s earnings last quarter?

Initiator Pharma A/S released its earnings results on Aug 21, 2026. The company reported -kr0.202 earnings per share for the quarter.

Is Initiator Pharma A/S overvalued?

According to Wall Street analysts Initiator Pharma A/S’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Initiator Pharma A/S pay dividends?

Initiator Pharma A/S does not currently pay dividends.

What is Initiator Pharma A/S’s EPS estimate?

Initiator Pharma A/S’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Initiator Pharma A/S have?

Initiator Pharma A/S has 68,452,890 shares outstanding.

What happened to Initiator Pharma A/S’s price movement after its last earnings report?

Initiator Pharma A/S reported an EPS of -kr0.202 in its last earnings report. Following the earnings report the stock price went up 2.372%.

Which hedge fund is a major shareholder of Initiator Pharma A/S?

Currently, no hedge funds are holding shares in SE:INIT

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Initiator Pharma A/S

Initiator Pharma A/S is a clinical-stage life sciences firm dedicated to discovering therapeutic solutions for critical unmet medical needs affecting the central and peripheral nervous systems. Its development pipeline features several clinical-phase compounds: IP2018, a monoamine reuptake inhibitor aimed at psychogenic erectile dysfunction; IPED2015, designed to address organic erectile dysfunction; and IPTN2021, an orphan drug candidate for severe neuropathic pain. Additionally, the company holds early-stage assets, including IPNP2015 for chronic pain management and IPDP2015 for depression. Established in 2016, Initiator Pharma A/S maintains its headquarters in Copenhagen, Denmark.